A biobank registry platform for cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates cancer patients who will undergo longitudinal profiling of circulating tumor DNA (ctDNA) biomarkers alongside their standard care treatments. It is a multicenter and multicohort study designed to gather data on ctDNA to better understand its role in oncology. Participants will provide blood samples at specific time points to facilitate this biomarker analysis, contributing to a biobank registry that may enhance future cancer research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥18 years of age
2. Willing to participate in the research
3. Able to provide informed consent
4. Must be diagnosed with cancer

Exclusion Criteria:

1\. Not willing or able to have additional blood samples collected

Where it's running

• Alabama Oncology
  Birmingham, Alabama, United States Recruiting
• PIH Health Whittier Hospital & PIH Health Physicians
  Whittier, California, United States Recruiting
• Eastern CT and Hematology and Oncology Associates
  Norwich, Connecticut, United States Recruiting
• Cancer Specialists of North Florida
  Jacksonville, Florida, United States Recruiting
• Morehouse
  Atlanta, Georgia, United States Recruiting
• Piedmont Healthcare
  Atlanta, Georgia, United States Recruiting

Study contacts

• Study coordinator: Lauren Lopez
• Email: aries@tempus.com
• Phone: 8007394137

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tempus Open Link registry for cancer patients using Olivia platform

  This registry tests whether Olivia can securely enroll cancer patients and combine their health data from EHRs and patient-reported outcomes to build a large, de-identified dataset.

  Recruiting Tempus AI · Chicago, Illinois · NCT07756034

• Using blood-based tumor DNA (ctDNA) to find leftover breast cancer after treatment

  This research will test whether a simple blood test that looks for tiny bits of tumor DNA can tell if people treated for breast cancer (including HR+/HER2-, HER2+, and triple-negative) still have leftover cancer or are at risk of recurrence.

  Recruiting at 16 sites Tempus AI · Birmingham, Alabama and 15 other locations · NCT07211178

• Longitudinal multi-center molecular biomarker registry for blood cancers

  This registry will collect serial blood samples and leftover tissue from people with AML or follicular lymphoma to see if molecular biomarkers predict disease course and treatment outcomes.

  Recruiting at 13 sites Tempus AI · Iowa City, Iowa and 12 other locations · NCT07154823

• AI-analyzed ECG to help find pulmonary hypertension in people with interstitial lung disease

  This project tests whether an AI-read 12-lead ECG can help doctors find hidden pulmonary hypertension in adults with interstitial lung disease.

  Recruiting at 41 sites Tempus AI · Birmingham, Alabama and 40 other locations · NCT06911632

• Longitudinal biomarker profiling for patients with head and neck cancer

  This study is trying to see how the molecular makeup of head and neck cancer changes over time in patients who are receiving first-line anti-PD1 or PDL1 therapy.

  Recruiting at 31 sites Tempus AI · Duarte, California and 31 other locations · NCT06163534

• Observational study on small cell lung cancer patients receiving standard care

  This study looks at small cell lung cancer patients receiving their usual treatment to see how their tumor and blood samples can help us understand the disease better and improve future treatments.

  Recruiting at 7 sites Tempus AI · Los Alamitos, California and 10 other locations · NCT05257551

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.